Results 31 to 40 of about 693,900 (279)
PARP inhibitors in castration-resistant prostate cancer
Cancer Treatment and Research Communications, 2020 Somatic or germline mutations in genes regulating DNA damage repair have been noted in around 20% of patients with advanced prostate cancer. Poly-ADP-ribose polymerase (PARP) inhibitors have shown encouraging efficacy in prostate cancer patients with DNA
Abhishek Tripathi +2 more
doaj +1 more source
Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury
Cells, 2022 Poly(ADP-ribose) polymerase 1 (PARP1), as a potential target for the experimental therapy of acute lung injury (ALI), was identified over 20 years ago.
Vanessa Martins +5 more
doaj +1 more source
Drug Design, Development and Therapy, 2022 Dehua Zhao, Xiaoqing Long, Jisheng Wang Department of Clinical Pharmacy, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, Sichuan, People’s Republic of ChinaCorrespondence: Dehua Zhao; Jisheng Wang, Email zhaoyaoshi0566@163.com ...
Zhao D, Long X, Wang J
doaj
PARP Inhibitors in Prostate Cancer [PDF]
Anticancer Research, 2021 Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in ...
Kabir, Grewal +2 more
openaire +2 more sources
Poly(ADP-Ribose) Polymerase (PARP) signaling of DNA damage induced by Topoisomerase 1 (TOP1) inhibition in carcinoma cells: chemotherapeutic implications of PARP and TOP1 inhibitors. [PDF]
, 2010 Una nuova strategia molecolare che incrementa l’azione antitumorale degli inibitori della Topoisomerasi 1 (TOP1) si basa sull’utilizzo di inibitori delle poli(ADP-ribosio) polimerasi (PARP).
D'Onofrio, Giovanna
core +1 more source
PARP Inhibitors for Chemoprevention—Letter [PDF]
Cancer Prevention Research, 2014 We read with great optimism To and colleagues' ([1][1]) article about PARP inhibitors as effective chemopreventive strategy for treating homologous repair (HR)–deficient tumors. Their overarching conclusion stated in the discussion is that “…synthetic lethality (i.e., PARP inhibitor ...
Saswati N, Chand +8 more
openaire +2 more sources
Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
Frontiers in Oncology, 2020 Purpose: PARP inhibitors are a novel targeted anti-cancer drug and a large number of clinical studies on PARP inhibitors have been accomplished. This updated meta-analysis was conducted to evaluate the efficacy and safety of PARP inhibitors in advanced ...
Yifan Jiang +9 more
doaj +1 more source
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Therapeutic Advances in Medical Oncology, 2017 Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer.
Tarra Evans, Ursula Matulonis
doaj +1 more source
Frontiers in Pharmacology, 2021 Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have breakthrough designations for metastatic castration-resistant prostate cancer (mCRPC). We performed a meta-analysis of current clinical trials to evaluate the efficacy of PARP inhibitors in ...
Kan Wu +5 more
doaj +1 more source
PARP inhibitors as anticancer agents
, 2021 The PARP enzyme family is a heterogeneous group of enzymes that are involved in a myriad of intracellular processes from maintaining genomic integrity, modulating inflammatory responses, and regulating cellular metabolism, to name a few.
Oladapo, Emmanuel Taiwo
core